– Cantor Global Healthcare Conference
presentation with live audio webcast on Monday, October 1st at 2:55
PM ET –
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or
the "Company"), a Phase 3 clinical-stage pharmaceutical company
focused on the development and commercialization of novel
therapeutics to treat inflammatory and fibrotic diseases by
leveraging its industry leading pipeline of endocannabinoid
system-targeting drug candidates, announced today that Yuval Cohen,
Ph.D., Chief Executive Officer of Corbus, will present at two
upcoming investor conferences in October.
The following are the details for the
conferences:
Event: Cantor Global Healthcare ConferenceDate:
Monday, October 1, 2018Time: 2:55 p.m. Eastern TimeLocation:
InterContinental New York Barclay Hotel, New York, NY
Event: Leerink Partners Roundtable Series: Rare
Disease & OncologyDate: Tuesday, October 2, 2018Time: 3:00 p.m.
Eastern TimeLocation: Lotte New York Palace, New York, NY
As part of his presentation, Dr. Cohen will
provide a corporate overview including the Company’s recently
announced transaction, the licensing of exclusive worldwide rights
to develop, manufacture and market drug candidates from more than
600 compounds targeting the endocannabinoid system from Jenrin
Discovery LLC. This pipeline includes candidate CRB-4001, a
CB1 inverse agonist that is scheduled to enter a Phase 1 study in
2019 followed by a NIH-supported Phase 2 study.
Dr. Cohen will also discuss in detail the
Company's four clinical development programs in diffuse cutaneous
systemic sclerosis ("SSc"), cystic fibrosis ("CF"), dermatomyositis
("DM") and systemic lupus erythematosus ("SLE") for lenabasum, its
novel, synthetic oral endocannabinoid-mimetic drug that is designed
to resolve chronic inflammation and halt fibrosis.
Corbus' RESOLVE-1 study, a multicenter,
randomized, double-blind Phase 3 study in SSc of lenabasum and its
Phase 2 study of lenabasum for the treatment of SLE are currently
underway. Additionally, patient enrollment and dosing are ongoing
in its Phase 2b multicenter, double-blinded, randomized,
placebo-controlled study of lenabasum for the treatment of CF. The
CF study will enroll approximately 415 patients with CF who are at
least 12 years of age and at increased risk for pulmonary
exacerbations. In support of the Phase 2b study, Corbus received a
Development Award for up to $25 million from the Cystic Fibrosis
Foundation. The Company recently announced its plans to initiate
its international Phase 3 study in approximately 150 adults with DM
before year end. The Phase 3 DM study will be a 1-year,
double-blind, randomized, placebo-controlled study testing efficacy
and safety of lenabasum.
Live audio webcast of both the presentations
will be accessible on the Events page of the Investors section of
Corbus website, www.corbuspharma.com, and will be archived on the
Company’s website for 90 days following the event.
About Lenabasum
Lenabasum (formerly known as anabasum) is a
synthetic, oral, small-molecule, selective cannabinoid receptor
type 2 (CB2) agonist that has been shown to preferentially bind to
CB2 expressed on activated immune cells and fibroblasts in animal
studies. CB2 activation triggers physiologic pathways that resolve
inflammation, speed bacterial clearance and halt fibrosis. CB2
activation also induces the production of specialized pro-resolving
lipid mediators that activate an endogenous cascade responsible for
the resolution of inflammation and fibrosis, while reducing
production of multiple inflammatory mediators. Through activation
of CB2, lenabasum also is believed to have a direct effect on
fibroblasts to halt tissue scarring. In preclinical and clinical
studies conducted so far, lenabasum has been shown to induce
resolution rather than immunosuppression by triggering biological
pathways to turn "off" chronic inflammation and fibrotic processes.
Lenabasum has demonstrated promising potency in preclinical models
of inflammation and fibrosis. Preclinical data and clinical studies
to date have shown lenabasum to have a favorable safety,
tolerability and pharmacokinetic profile. Data to date suggest that
the drug may have clinical benefit as well as a beneficial impact
on inflammatory and immunological markers in Phase 2 studies in
diffuse cutaneous systemic sclerosis, dermatomyositis and cystic
fibrosis. Additional clinical studies are being conducted and/or
planned to confirm these preliminary results and support
applications for regulatory approval.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat inflammatory
and fibrotic diseases by leveraging its industry leading pipeline
of endocannabinoid system-targeting drug candidates. The Company's
lead product candidate, lenabasum, is a novel, synthetic, oral,
selective cannabinoid receptor type 2 (CB2) agonist designed to
resolve chronic inflammation and fibrotic processes. Lenabasum is
currently being evaluated in systemic sclerosis, cystic fibrosis,
dermatomyositis, and systemic lupus erythematosus.
Corbus licensed the exclusive worldwide rights
to develop, manufacture and market drug candidates from more than
600 compounds targeting the endocannabinoid system from Jenrin
Discovery LLC. The pipeline includes CRB-4001, a 2nd generation,
peripherally-restricted, selective cannabinoid receptor type 1
(CB1) inverse agonist specifically designed to eliminate
blood-brain barrier penetration and brain CB1 receptor occupancy
that mediate the neuropsychiatric issues associated with
first-generation CB1 inverse agonists. Potential indications for
CRB-4001 include NASH, primary biliary cholangitis, idiopathic
pulmonary fibrosis, radiation-induced pulmonary fibrosis,
myocardial fibrosis after myocardial infarction and acute
interstitial nephritis, among others. CRB-4001 is scheduled to
enter a Phase 1 study in 2019 followed a National Institutes of
Health (NIH)-funded first-in-patient Phase 2 study.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Source: Corbus Pharmaceuticals Holdings, Inc.
###
Investor Contacts:
Institutional Investor Inquiries
Ted Jenkins, Senior Director, Investor Relations and Communications
Corbus Pharmaceuticals, Inc.
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com
All Other Investor Inquiries
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (833) 475-8247
Email: crbp@jtcir.com
Media Contact
Eliza Schleifstein
Scient Public Relations
Phone: + 1 (917) 763-8106
Email: eliza@scientpr.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024